ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 ( DrugBank: ACR-16 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 8 | Huntington disease | 12 |
8. Huntington disease
Clinical trials : 242 / Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-000904-24-NL (EUCTR) | 15/02/2016 | 17/02/2016 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Germany;Netherlands;Italy;United Kingdom | ||
| 2 | EUCTR2015-000904-24-DE (EUCTR) | 03/12/2015 | 04/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | Poland;Austria;Australia;France;United States;Canada;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 3 | EUCTR2015-000904-24-AT (EUCTR) | 18/11/2015 | 15/09/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 19.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Phase 2 | France;United States;Canada;Poland;Denmark;Australia;Austria;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 4 | EUCTR2015-000904-24-GB (EUCTR) | 13/11/2015 | 18/08/2015 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington’s Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 300 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | France;United States;Canada;Poland;Austria;Australia;Russian Federation;Netherlands;Germany;Italy;United Kingdom | ||
| 5 | EUCTR2015-000904-24-IT (EUCTR) | 15/09/2015 | 23/02/2018 | A study testing if pridopidine is safe and efficacious in patients with Huntington's Disease | A Multi-Center, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Pridopidine in Patients with Huntington's Disease - Open PRIDE-HD | Huntington's disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidina Product Code: TV-7820 INN or Proposed INN: Pridopidina Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | France;United States;Canada;Poland;Denmark;Austria;Australia;Russian Federation;Netherlands;Germany;United Kingdom;Italy | ||
| 6 | EUCTR2013-001888-23-DK (EUCTR) | 13/04/2015 | 08/01/2015 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Denmark;Australia;Germany;Netherlands | ||
| 7 | EUCTR2013-001888-23-PL (EUCTR) | 23/07/2014 | 14/05/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 8 | EUCTR2013-001888-23-AT (EUCTR) | 01/07/2014 | 08/01/2014 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 9 | EUCTR2013-001888-23-NL (EUCTR) | 07/04/2014 | 20/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Netherlands;Germany | ||
| 10 | EUCTR2013-001888-23-DE (EUCTR) | 25/03/2014 | 10/12/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 19.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands | ||
| 11 | EUCTR2013-001888-23-IT (EUCTR) | 13/03/2014 | 11/12/2013 | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 14.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Not Recruiting | Female: yes Male: yes | 400 | Phase 2 | Netherlands;United States;Austria;Russian Federation;Italy;United Kingdom;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany | ||
| 12 | EUCTR2013-001888-23-GB (EUCTR) | 22/01/2014 | 27/11/2013 | A study testing different doses of pridopidine (45 mg, 67.5 mg, 90 mg, 112.5 mg twice-daily) against placebo to establish which one works best and is safe when treating certain symptoms of patients with Huntington´s Disease. | A Phase 2, Dose-Finding, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study, Evaluating the Safety and Efficacy of Pridopidine 45 mg, 67.5 mg, 90 mg, and 112.5 mg Twice-Daily versus Placebo for Symptomatic Treatment in Patients with Huntington’s Disease | Huntington’s disease MedDRA version: 17.1;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 Product Name: Pridopidine Product Code: TV-7820 INN or Proposed INN: pridopidine Other descriptive name: ACR16 hydrochloride, ASP2314 hydrochloride, FR310826 | Teva Branded Pharmaceutical Products R&D, Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 400 | Phase 2 | United States;Austria;Russian Federation;United Kingdom;Italy;France;Czech Republic;Canada;Poland;Australia;Denmark;Germany;Netherlands |